IMGN · ImmunoGen
Acquired Company
AbbVie completed the acquisition of ImmunoGen on 2/12/2024 for $31.26 per share in cash, valuing ImmunoGen at approximately $10.1 billion.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company is headquartered in Waltham, Massachusetts.
830 WINTER STREET, WALTHAM, MA, UNITED STATES, 02451-1477, Massachusetts, 02109-2202, USA
BIOTECHNOLOGY
HEALTHCARE
Market Cap
8.724B
52 Wk Range
$0.00 - $0.00
Previous Close
$31.23
Open
$31.23
Volume
N/A
Day Range
$31.23 - $31.23
Enterprise Value
N/A
Cash
605.5M
Avg Qtr Burn
N/A
Insider Ownership
0.32%
Institutional Own.
86.52%
Qtr Updated
Sep 30th 2023